Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-01

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Methodology: The 70 patients of age 20 to 50 years presented to the out-patient department of CMH Abbottabad suffering from alopecia areata were enrolled. The non-probability consecutive sampling technique was used. Patient in group-A applied clobetasol propionate 0.05% twice daily, whereas Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months. The Patients were assessed at baseline, 4th weeks, 8th week and 12th week after treatment of each session. Hair loss was calculated from SALT score at presentation and on follow-up after 3 months. The degree of response was assessed on the basis of hair re-growth as excellent (\>75% re-growth), Marked (51-75% re-growth), moderate (26-50% re-growth), or slight (≤25% re-growth). To determine statistical significance χ2-square test, taking p-value \<0.05 as significant, was used.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Oral Tofacitinib in the Treatment of Alopecia Areata

NCT06157905

Extensive Alopecia Areata

COMPLETED EARLY_PHASE1

Various Procedural Treatment Options for Androgenetic Alopecia

NCT06826001

Androgenetic Alopecia

NOT_YET_RECRUITING PHASE2

Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata

NCT03535233

Alopecia Areata

COMPLETED PHASE4

Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.

NCT06278402

Alopecia Areata Alopecia Totalis Alopecia Universalis

COMPLETED PHASE3

Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata

NCT02350023

Alopecia Areata

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alopecia Areata

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A applied Clobetasol Propionate 0.05%

Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months.

Group Type ACTIVE_COMPARATOR

Group A applied topical Clobetasol Propionate

Intervention Type DRUG

Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months

Group B applied topical Tacrolimus 0.1%

Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.

Group Type ACTIVE_COMPARATOR

Group B applied topical Tacrolimus

Intervention Type DRUG

Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Group A applied topical Clobetasol Propionate

Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months

Intervention Type DRUG

Group B applied topical Tacrolimus

Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients age 20 to 50 years
* Both male and female
* Duration of illness less than 2 months
* those who never received any treatment before

Exclusion Criteria

* Patients having duration of alopecia greater than 2 months
* Atypical alopecia areata i.e., Alopecia universalis etc
* Hypersensitivity history to topical corticosteroids or tacrolimus
* patients taking any systemic immune suppression
* pregnancy/lactation

Minimum Eligible Age

20 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No